Bio

Colin Chapman is a partner in our Silicon Valley office, specializing in the areas of corporate partnering and strategic alliances, technology protection, and licensing and commercialization of intellectual property and technology assets. Colin’s focus is representing emerging growth companies both in the United States and abroad. Additionally, Colin has considerable experience representing venture capitalists and multinational companies requiring such expertise. Colin represents his clients in negotiating strategic alliances and/or licensing and commercial arrangements with companies such as Amazon, Apple, BMW, Bristol Myers Squibb, Cardinal Health, Chevron Corporation, Cisco, Disney, Exxon-Mobile, Ford, Intel, JP Morgan Chase, Kaiser, Pfizer, Roche, Salesforce.com, Tesla, Thermo Fisher Scientific and Visa. He has also negotiated commercial and clinical arrangements with many major research institutions. Colin has spoken in a number of forums and authored articles and books on intellectual property matters and related business strategies that affect strategic alliances. He is an author of the treatise, “Corporate Partnering, Structuring and Negotiating Domestic and International Strategic Alliance” (Aspen Publishers), and a Chapter author of both “The Acquisition and Sale of the Emerging Growth Company: The M&A Exit” (Glasser Legal Works) and “Venture Capital and Public Offering Negotiation” (Aspen Publishers). He is also an invited speaker at numerous conferences including with the Practicing Law Institute, the Biotechnology Law Institute, the Technology Transfer Conference, and Executive Programs at the Stanford Graduate School of Business.